Treatment of unscheduled bleeding in women using extended- or continuous-use combined hormonal contraception: a systematic review

Patient satisfaction with two different management modalities for erratic bleeding during continuous hormone therapy for endometriosis-associated symptoms: A before-after study

OBJECTIVE

To evaluate patient satisfaction with the management of erratic bleeding during continuous hormone therapy for endometriosis using two different strategies: an active approach (tailored cycling), which involved discontinuation of the therapy; and a passive approach, which involved waiting for spontaneous resolution of the bleeding.

METHODS

This was an observational before-after study. All patients enrolled within a previously defined time limit were instructed to adopt a passive strategy to manage erratic bleeding, while all patients enrolled after that defined time were instructed to discontinue therapy for 7 days (tailored cycling). Degree of satisfaction, characteristics of bleeding, and level of dysmenorrhoea were compared and analysed at the time of enrolment and after 6 and 12 months.

RESULTS

In total, 201 patients were included in the study. Satisfaction was 29% higher among patients in the passive strategy group compared with those in the tailored cycling group; this difference was significant. No significant differences were identified for the other outcomes.

CONCLUSION

Patients may be more satisfied with the use of a passive approach to manage irregular bleeding during continuous hormone therapy for endometriosis-associated pain. All patients should be provided with comprehensive information regarding all available management strategies for unpredictable irregular bleeding. This will enable patients to make informed decisions based on their personal experience and preferences, without external pressure, thus improving compliance, adherence and, ideally, satisfaction with treatment.

Removal of an incarcerated intrauterine device reaching the serosal surface of the uterus by hysteroscopy alone: a case report

Background

An intrauterine device (IUD) is a widely used long-term contraceptive device for family planning. However, the IUD can lead to various complications. Severe complications and remedial measures caused by IUDs have been reported in the literature; however, detailed surgical approaches for safely removing the IUD within the minimum surgical range have rarely been described especially in postmenopausal women. Therefore, this article aims to share our surgical experience in removing an IUD that had reached the serosal surface of the uterus using hysteroscopy alone after menopause to provide new clinical ideas.

Case introduction

We report the case of a 63-year-old Chinese patient with a 12-year history of menopause. She had an IUD placed after an abortion more than 30 years ago. She came to the hospital because of occasional a small amount of unprovoked vaginal bleeding, the preoperative examination suggested an embedded IUD that appeared to have reached the serosal surface of the uterus. The IUD was not visible during hysteroscopic surgery because of uterine adhesions. Microscissors were employed to cut along the white adhesion band, revealing a faintly visible metal wire. We successfully removed the IUD using hysteroscopy only. The patient has recovered well after surgery and has been in good health for more than 5 months, with no complaints of abdominal pain or vaginal bleeding.

Conclusion

This case suggests that hysteroscopic exploration can be performed in patients whose preoperative examination indicates that the IUD has reached or protrudes from the serosal surface of the uterus. If necessary, laparoscopic or open surgery can be performed. For patients whose IUD is not visible in the uterine cavity, preoperative imaging can help assess the thickness of the uterine myometrium and the distance to the serosal surface. Intraoperatively, scissors can cut through tissue or adhesions, and instruments can measure the separation distance or visualize the device within the adhesions. In addition, it is crucial to know the patient's expectations, assess the pros and cons, and discontinue the procedure if necessary.

U.S. Selected Practice Recommendations for Contraceptive Use, 2024

The 2024 U.S. Selected Practice Recommendations for Contraceptive Use (U.S. SPR) addresses a selected group of common, yet sometimes complex, issues regarding initiation and use of specific contraceptive methods. These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national experts in Atlanta, Georgia, during January 25-27, 2023. The information in this report replaces the 2016 U.S. SPR (CDC. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR 2016;65[No. RR-4]:1-66). Notable updates include 1) updated recommendations for provision of medications for intrauterine device placement, 2) updated recommendations for bleeding irregularities during implant use, 3) new recommendations for testosterone use and risk for pregnancy, and 4) new recommendations for self-administration of injectable contraception. The recommendations in this report are intended to serve as a source of evidence-based clinical practice guidance for health care providers. The goals of these recommendations are to remove unnecessary medical barriers to accessing and using contraception and to support the provision of person-centered contraceptive counseling and services in a noncoercive manner. Health care providers should always consider the individual clinical circumstances of each person seeking contraceptive services. This report is not intended to be a substitute for professional medical advice for individual patients; when needed, patients should seek advice from their health care providers about contraceptive use.

Dislocated intrauterine devices: clinical presentations, diagnosis and management

OBJECTIVE

Intrauterine devices (IUDs) are globally one of the most popular methods of contraception. Uterine perforation is one of the most significant complications of IUD use and commonly occurs at the time of IUD insertion rather than presenting as delayed migration. This paper reports a series of 13 cases of displaced IUDs requiring retrieval by laparoscopy or laparotomy. All the IUDs were copper bearing and most perforations occurred immediately after IUD insertion.

CASES

In two patients with sigmoid colon injury and IUD penetration of the appendix, laparoscopic management had failed and laparotomy was necessary owing to severe obliteration of the pelvic cavity. In one patient laparotomy was the preferred surgical approach owing to acute bowel perforation. In the remaining patients, the displaced devices were successfully removed by laparoscopy.

CONCLUSION

Uterine perforation and IUD migration to the organs in the abdominopelvic cavity are serious complications of IUD insertion and can be successfully managed by laparoscopy, or by laparotomy in the presence of severe pelvic adhesions or unexpected complications.

No. 329-Canadian Contraception Consensus Part 4 of 4 Chapter 9: Combined Hormonal Contraception

OBJECTIVE

To provide guidelines for health care providers on the use of contraceptive methods to prevent pregnancy and on the promotion of healthy sexuality.

OUTCOMES

Overall efficacy of cited contraceptive methods, assessing reduction in pregnancy rate, safety, and side effects; the effect of cited contraceptive methods on sexual health and general well-being; and the availability of cited contraceptive methods in Canada.

EVIDENCE

Medline and the Cochrane Database were searched for articles in English on subjects related to contraception, sexuality, and sexual health from January 1994 to December 2015 in order to update the Canadian Contraception Consensus published February-April 2004. Relevant Canadian government publications and position papers from appropriate health and family planning organizations were also reviewed.

VALUES

The quality of the evidence is rated using the criteria described in the Report of the Canadian Task Force on Preventive Health Care. Recommendations for practice are ranked according to the method described in this report.

SUMMARY STATEMENTS

RECOMMENDATIONS.

Use of Combined Oral Contraceptives in Perimenopausal Women

While perimenopausal women have low fecundity, they are still capable of becoming pregnant and the majority of pregnancies occurring during perimenopause are unintended pregnancies. Therefore, even during perimenopause, contraception must be used if unintended pregnancies are to be avoided. However, many perimenopausal women and healthcare providers believe that older people should not take combined oral contraceptives (COC) because doing so may be dangerous. However, to date, there is no evidence that taking COC presents an increased risk of cardiovascular events or breast cancer for middle-aged women as compared to other age groups, and in their recommendations, the Centers for Disease Control and Prevention (CDC) also do not list age itself as a contraindication for COC. Perimenopausal women often experience menstrual irregularity, heavy menstrual bleeding, and vasomotor symptoms. Taking COCs can help control these symptoms and significantly reduce the risk of ovarian cancer, endometrial cancer, and colorectal cancer. The objective of the present review is to examine the usage methods of COC among perimenopausal women and the health issues that may arise from taking COC in perimenopausal women.

Extended regimens of combined hormonal contraception to reduce symptoms related to withdrawal bleeding and the hormone-free interval: a systematic review of randomised and observational studies

OBJECTIVE

To assess whether continuous and extended regimens (CRs/ERs) of combined hormonal contraceptives (CHCs) improve symptoms related to withdrawal bleeding or the hormone-free interval and to compare the efficacy, safety, and cost of CRs/ERs to those of conventional 28-day regimens.

STUDY DESIGN

A literature search of the PubMed database was conducted for randomised clinical trials (RCTs) and observational studies published in any language between 2006 and 2013.

RESULTS

Sixteen RCTs and 14 observational studies evaluated issues related to our objectives. CRs/ERs, whose efficacy and safety were comparable to those described for conventional regimens, were preferred due to their improvement of symptoms related to withdrawal bleeding or the hormone-free interval and the lower costs resulting from the reduced incidence of these symptoms.

CONCLUSION

The contraceptive efficacy and safety of CR/ER use of CHCs is at least equal to that of 28-days conventional regimens, and this use may have some cost savings. CRs/ERs are recommended for women willing to take a CHC for treatment of symptoms related to withdrawal bleeding or the hormone-free interval.